# Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

> **NCT00171899** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 80 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00171899
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171899, "Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00171899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*